A 100% run, a sidelined CFO, and a guidance raise: Fortrea's turnaround rally meets its leadership test
Bookings keep climbing and the P&L is healing, but the new CFO can't start due to a restrictive-covenant fight — the market has to weigh momentum against governance risk.
FTRE · Earnings Call · 2026-07-29
Leadership turbulence in the middle of a turnaround
Fortrea's second-quarter print was supposed to be the payoff — a beat, a guidance raise, a fourth straight quarter of book-to-bill above 1.0x. Instead, the headline is the CFO who can't start.
Our new CFO, Jason Madlock, is not currently able to act as a CFO for Fortrea due to an ongoing proceeding relating to restrictive covenants with his former employer. While I will not comment on the specifics, we believe we've acted appropriately in connection with Jason's appointment and plan to support Jason as we work through this matter.
The company replaced him immediately with board member David Smith (a former Charles River CFO) on an interim basis and handed the Audit Committee to Aaron Russell. For a three-year-old spin-out trying to convince a skeptical market it is finally turning the corner, this is exactly the kind of self-inflicted uncertainty that makes Chinese biotechs and other newer clients pause. Yet the stock has barely flinched: after doubling in the last 90 trading days, it has given back only ~11% from its July 28 peak.
The numbers finally back the talk
The improvement underneath is genuine. The operating margin, which cratered to -84% in Q1 2025 on a multi-hundred-million goodwill charge, has recovered to roughly -1.9%. Revenue is still falling — Q2 came in at $678.2M, down 4.5% year over year, with the full-year guide of $2.62B-$2.69B implying a modest decline for 2026 — but the engine underneath is improving. Jill McConnell's swan-song remarks cited lower pass-through costs, FSP headwinds, and service-fee growth in Clinical Pharmacology. Anshul Thakral framed the margin pickup as mix-driven and operational:
“as we continue to grow and diversify our bookings and diversify the backlog that is now burning off into revenue, we're seeing some higher-margin projects burning off into revenue.” — Anshul Thakral, Chief Executive Officer · 2026-07-29
This is in line with the cadence management laid out at the start of the year, when Jill McConnell told analysts the trajectory would be more of a steady grind than a leap:
“You're not going to see the big step-up... it's going to be much more measured this quarter... a slow gradual increase over the course of the year.” — Jill McConnell, Chief Financial Officer · 2026-05-05
The commercial engine is firing: $720.4M of net new business weighted toward biotech, book-to-bill of 1.06x in Q2 and 1.12x on a trailing-twelve-month basis, and first-half awards up 19% year over year — the fourth consecutive quarter of book-to-bill above 1.0x. The Biotech funding backdrop is improving, and management explicitly credits its own execution rather than just the market, a claim echoed when Anshul noted competitive behavior has normalized:
“some of the temporal irrational behavior we saw on pricing in FSP, that has subsided and those processes were completed last year. What I'm seeing in 2026 is a return back to a normal environment.” — Anshul Thakral, Chief Executive Officer · 2026-07-29
The recovery in biotech decision-making was already visible a quarter ago, with the CEO flagging a speedier rebound among smaller sponsors:
“We are seeing a little bit speedier recovery in the biotech space.” — Anshul Thakral, Chief Executive Officer · 2026-05-05
AI as the narrative hook — but a slow burn
The company's freshest talking point is its AI capabilities: the Fortrea Intelligent Technology (FIT) platform and a company-wide rollout of Microsoft Copilot to roughly 14,000 staff. Management is careful to frame AI as a force-multiplier rather than a job-killer:
“these changes will take time for them to show meaningful differentiation on the commercial side and for them to show a meaningful impact on the operational side.” — Anshul Thakral, Chief Executive Officer · 2026-07-29
That is a deliberate softening of expectations. Most RFPs now ask about AI, so Fortrea needs a credible roadmap just to stay in the room — but leaders concede it is not yet a deal-winner. The risk is that the market, having bid the stock up over 100% in 90 days, wants AI to move the needle faster than a regulated, GCP-bound clinical trial operation realistically can.
What the market is pricing
The tape is the tell: shares touched ~$20.70 on July 28 — the day before the call — before giving back roughly 11%. At a market cap around $1.3B and a price-to-revenue multiple of just 0.3x, the market is paying for the thesis that margins keep expanding as service-fee mix improves and the $7.8B backlog burns at a healthier 8.6%. The balance sheet remains the leash: net debt sits near $900M, though management has cut it about 35% from the spin's level and expects positive free cash flow for the full year. Customer concentration is still notable — the top 10 accounts drove 55.4% of revenue — but cancellations held in line with historical trends.
The prior calls established the roadmap; this one reaffirmed it with a raised guide. What is genuinely new is the leadership whiplash. Whether a CFO mired in a non-compete dispute becomes a footnote or the next quarter's headline will say a lot about whether Fortrea's turnaround has the operating steadiness to match its stock's newfound momentum.